Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens

Luisa Escobar Hoyos; Omar Abdel-Wahab

doi:10.1016/j.ccell.2018.07.008

Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens

Cancer Cell. 2018 Aug 13;34(2):181-183. doi: 10.1016/j.ccell.2018.07.008.

Authors

Luisa Escobar Hoyos¹, Omar Abdel-Wahab²

Affiliations

¹ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 408 E. 69th Street, New York, NY 10065, USA; David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Pathology, Stony Brook University, New York, NY 10065, USA.
² Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, 408 E. 69th Street, New York, NY 10065, USA; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: abdelwao@mskcc.org.

Abstract

In this issue of Cancer Cell, Kahles et al. perform a comprehensive analysis of RNA splicing across cancer types and identify novel correlations between genetic alterations and splicing in cancer. In addition, they identify that tumor-specific splicing has the potential to generate a large new class of tumor-specific neoantigens.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Alternative Splicing*
Antigens
Humans
Mutation
Neoplasms*
RNA Splicing

Substances

Antigens

Abstract

Publication types

MeSH terms

Substances

Grants and funding